The objective of this work was to conduct an ontogenetic and structural study of the urachus. We studied 40 human fetuses (13–20 weeks post conception, WPC). The urachus was stained in Masson’s trichrome, to quantify connective tissue and smooth muscle and to determine the urachal lumen area. Weigert’s resorcin-fuchsin was used to observe elastic fibers, and picrosirius red and immunohistochemistry analysis were used to observe collagen. The images were captured with Olympus BX51 microscopy and an Olympus DP70 camera. The stereological analysis was done using the software Image Pro and Image J, to determine volumetric densities. For biochemical analysis, the collagen concentrations were expressed per milligram of dry tissue. Means were compared using the unpaired t test (p < 0.05). Quantitative analysis documented a statistically insignificant increase (p = 0.1475) in volumetric densities of smooth muscle in the urachus of males (23.02%), when compared with females (18.43%), and a statistically significant increase (p = 0.0439) in volumetric densities of connective tissue in the urachus of females, (67.64%) when compared with males (58.38%). Total collagen concentrations in the male (31,919–56.792 µg/mg, mean 45,656) and female fetuses (33,485–48,527 µg/mg, mean 42,308) did not differ significantly (p = 0.5912). At higher gestational ages, the urachal lumen area was smaller. In 13th WPC fetuses, the urachal lumen area was 16,301 µm2 and in 17th WPC fetuses, the urachal lumen area was 1,676 µm2. We determined that the urachal lumen was closed from the 17th WPC in all fetuses.

Keywords:
Urachus, Bladder, Development, Urachal anomalies, Urachal patency, Human fetuses
1.
Ashley, R.A., B.A. Inman, T.J. Sebo, B.C. Leibovich, M.L. Blute, E.D. Know, H. Zincke (2006) Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer 107: 712–720.
2.
Bastos, A.I., E.A. Silva, W.S. Costa, F.J.B. Sampaio (2004) The concentration of elastic fibers in the male urethra during human fetal development. BJU Int 94: 620–623.
3.
Begg, C. (1930) The urachus: its anatomy, histology and development. J Anat 64: 170–183.
4.
Bergman, I., R. Loxley (1963) Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Biochem 35: 1961–1965.
5.
Cabral, C.A.P., F.J.B. Sampaio, L.E.M. Cardoso (2003) Analysis of the modifications in the composition of bladder glycosaminoglycan and collagen as a consequence of changes in sex hormones associated with puberty or oophorectomy in female rats. J Urol 170: 2512–2516.
6.
Cavalcanti, A.G., W.S. Costa, L.S. Baskim, J.A. McAninch, F.J. Sampaio (2007) A morphometric analysis of bulbar urethral strictures. BJU Int 100: 397–402.
7.
Choi, Y.J., J.M. Kim, S.Y. Ahn, J. Oh, S.W. Han, J.S. Lee (2006) Urachal anomalies in children: a single center experience. Yonsei Med J 47: 782–786.
8.
Cilento, B.G., S.B. Bauer, A.B. Retik, C.A. Peters, A. Atala (1998) Urachal anomalies: defining the best diagnostic modality. Urology 52: 120–122.
9.
Favorito, L.A., T.M. Cardinot, A.R.M. Morais, F.J.B. Sampaio (2004) Urogenital anomalies in human male fetuses. Early Hum Dev 79: 41–47.
10.
Gobet, R., J. Bleakley, C.A. Peters (1998) Premature urachal closure induces hydroureteronephrosis in male fetuses. J Urol 160: 1463–1467.
11.
Hern, W.M. (1984) Correlation of fetal age and measurements between 10 and 26 weeks of gestation. Obstet Gynecol 63: 26–32.
12.
Homsy, Y.L. (1997) Bladder and urachus; in O’Donnell, B., A.S. Koff (eds): Pediatric Urology, ed 3. Oxford, Butterworth-Heinemann, pp 482–494.
13.
Kaefer, M., M.A. Keating, M.C. Adams, R.C. Rink (1995) Posterior urethral valves, pressure pop-offs and bladder function. J Urol 154: 708–711.
14.
Lattimer, J.K. (1958) Congenital deficiency of the abdominal musculature and associated genitourinary anomalies: a report of 22 cases. J Urol 79: 343–352.
15.
McCrystal, D.J., M.J. Ewing, A.L. Lambrianides (2001) Acquired urachal pathology: presentation of five cases and a review of the literature. ANZ J Surg 71: 774–776.
16.
Mercer, B.M., S. Sklar, A. Shariatmadar, M.S. Gillieson, M.K. D’Alton (1987) Fetal foot length as a predictor of gestational age. Am J Obst Gynecol 156: 350–356.
17.
Nascimento, A.F., P.D. Cin, B.G. Cilento, A.R. Perez-Atayde, H.P.W. Kozakewich, V. Nose (2004) Urachal inflammatory myofibroblastic tumor with alk gene rearrangement: a study of urachal remnants. Urology 64: 140–143.
18.
Okegawa, T., A. Odagane, K. Nutahara, E. Higashihara (2006) Laparoscopic management of urachal remnants in adulthood. Int J Urol 13: 1466–1469.
19.
Platt, L.D., A.L. Medearis, G.R. DeVore, J.M. Horenstein, D.E. Carlson, H.S. Brar (1988) Fetal foot length: relationship to menstrual age and fetal measurements in the second trimester. Obstet Gynecol 71: 526–531.
20.
Stephens, F.D., E.D. Smith, J.M. Hutson (2002) Congenital Anomalies of the Kidney, Urinary and Genital Tracts, ed 2. London, Martin Dunitz.
21.
Sulak, O., N. Cankara, M.A. Malas, E. Cetin, K. Desdicioglu (2008) Anatomical development of the normal urachus during the fetal period. Saudi Med J 29: 30–35.
22.
Yapok, B.R., B. Gorges, A.J. Holland (2008) Investigation and management of suspected urachal anomalies in children. Pediatr Surg Int 24: 589–592.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.